File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/cam4.4888
- WOS: WOS:000803716400001
Supplementary
-
Citations:
- Web of Science: 0
- Appears in Collections:
Article: Clinical characteristics, risk factors and outcomes of cancer patients with COVID-19: A population-based study
Title | Clinical characteristics, risk factors and outcomes of cancer patients with COVID-19: A population-based study |
---|---|
Authors | |
Issue Date | 2022 |
Citation | Cancer Medicine, 2022 How to Cite? |
Abstract | Introduction Cancer patients may be susceptible to poorer outcomes in COVID-19 infection owing to the immunosuppressant effect of chemotherapy/radiotherapy and cancer growth, along with the potential for nosocomial transmission due to frequent hospital admissions. Methods This was a population-based retrospective cohort study of COVID-19 patients who presented to Hong Kong public hospitals between 1 January 2020 and 8 December 2020. The primary outcome was a composite endpoint of requirement for intubation, ICU admission and 30-day mortality. Results The following study consisted of 6089 COVID-19 patients (median age 45.9 [27.8.1–62.7] years; 50% male), of which 142 were cancer subjects. COVID-19 cancer patients were older at baseline and tended to present with a higher frequency of comorbidities, including diabetes mellitus, hypertension, chronic obstructive pulmonary disease, ischemic heart disease, ventricular tachycardia/fibrillation and gastrointestinal bleeding (p < 0.05). These subjects also likewise tended to present with higher serum levels of inflammatory markers, including D-dimer, lactate dehydrogenase, high sensitivity troponin-I and C-reactive protein. Multivariate Cox regression showed that any type of cancer presented with an almost four-fold increased risk of the primary outcome (HR: 3.77; 95% CI: 1.63–8.72; p < 0.002) after adjusting for significant demographics, Charlson comorbidity index, number of comorbidities, past comorbidities and medication history. This association remained significant when assessing those with colorectal (HR: 5.07; 95% CI: 1.50–17.17; p < 0.009) and gastrointestinal malignancies (HR: 3.79; 95% CI: 1.12–12.88; p < 0.03), but not with lung, genitourinary, or breast malignancies, relative to their respective cancer-free COVID-19 counterparts. Conclusions COVID-19 cancer patients are associated with a significantly higher risk of intubation, ICU admission and/or mortality. |
Persistent Identifier | http://hdl.handle.net/10722/313409 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhou, J | - |
dc.contributor.author | Lakhani, I | - |
dc.contributor.author | Chou, O | - |
dc.contributor.author | Leung, KSK | - |
dc.contributor.author | Lee, TTL | - |
dc.contributor.author | Wong, MV | - |
dc.contributor.author | LI, Z | - |
dc.contributor.author | Wai, KCA | - |
dc.contributor.author | Chang, C | - |
dc.contributor.author | Wong, ICK | - |
dc.contributor.author | Zhang, Q | - |
dc.contributor.author | Tse, G | - |
dc.contributor.author | Cheung, BMY | - |
dc.date.accessioned | 2022-06-17T06:45:58Z | - |
dc.date.available | 2022-06-17T06:45:58Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Cancer Medicine, 2022 | - |
dc.identifier.uri | http://hdl.handle.net/10722/313409 | - |
dc.description.abstract | Introduction Cancer patients may be susceptible to poorer outcomes in COVID-19 infection owing to the immunosuppressant effect of chemotherapy/radiotherapy and cancer growth, along with the potential for nosocomial transmission due to frequent hospital admissions. Methods This was a population-based retrospective cohort study of COVID-19 patients who presented to Hong Kong public hospitals between 1 January 2020 and 8 December 2020. The primary outcome was a composite endpoint of requirement for intubation, ICU admission and 30-day mortality. Results The following study consisted of 6089 COVID-19 patients (median age 45.9 [27.8.1–62.7] years; 50% male), of which 142 were cancer subjects. COVID-19 cancer patients were older at baseline and tended to present with a higher frequency of comorbidities, including diabetes mellitus, hypertension, chronic obstructive pulmonary disease, ischemic heart disease, ventricular tachycardia/fibrillation and gastrointestinal bleeding (p < 0.05). These subjects also likewise tended to present with higher serum levels of inflammatory markers, including D-dimer, lactate dehydrogenase, high sensitivity troponin-I and C-reactive protein. Multivariate Cox regression showed that any type of cancer presented with an almost four-fold increased risk of the primary outcome (HR: 3.77; 95% CI: 1.63–8.72; p < 0.002) after adjusting for significant demographics, Charlson comorbidity index, number of comorbidities, past comorbidities and medication history. This association remained significant when assessing those with colorectal (HR: 5.07; 95% CI: 1.50–17.17; p < 0.009) and gastrointestinal malignancies (HR: 3.79; 95% CI: 1.12–12.88; p < 0.03), but not with lung, genitourinary, or breast malignancies, relative to their respective cancer-free COVID-19 counterparts. Conclusions COVID-19 cancer patients are associated with a significantly higher risk of intubation, ICU admission and/or mortality. | - |
dc.language | eng | - |
dc.relation.ispartof | Cancer Medicine | - |
dc.title | Clinical characteristics, risk factors and outcomes of cancer patients with COVID-19: A population-based study | - |
dc.type | Article | - |
dc.identifier.email | Wai, KCA: awai@hku.hk | - |
dc.identifier.email | Wong, ICK: wongick@hku.hk | - |
dc.identifier.email | Cheung, BMY: mycheung@hkucc.hku.hk | - |
dc.identifier.authority | Wai, KCA=rp02261 | - |
dc.identifier.authority | Wong, ICK=rp01480 | - |
dc.identifier.authority | Cheung, BMY=rp01321 | - |
dc.identifier.doi | 10.1002/cam4.4888 | - |
dc.identifier.hkuros | 333482 | - |
dc.identifier.isi | WOS:000803716400001 | - |